Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings

References

• Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69(7):1286–91.
   PubMed Web of Science ®Google Scholar
• Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther 2013;15(5):R135.
   PubMed Web of Science ®Google Scholar
• Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008;18(5):460–4.
   PubMed Web of Science ®Google Scholar
• Oliver B, Elodie M, Christine A, Christian G, Philippe F, Christian HR, et al. Effect of discontinuing TNF alpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009;76:350–5.
   PubMed Web of Science ®Google Scholar
• Josef SS, Peter N, Patrick D, Stephen H, Elena I, Fedra IP, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918–29.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kishimoto M, Helga R, Matsui K, Okada M, Saeki Y, et al. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Rheumatology 2016;55(2):286–90.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Oba K, Koike T, Miyasaka N, Mimori T, Takeuchi T, et al. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis 2020;79(1):94–102.
   PubMed Web of Science ®Google Scholar
• Josef SS, Paul E, Roy F, Ronald FV, Karel P, Patrick D, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Lancet 2014;25:321–32.
   Google Scholar
• Jacqueline D, Hans B, Joachim L, Anja W, Siegfried W, Anke L, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844–50.
   PubMed Web of Science ®Google Scholar
• Van den Broek M, Klarenbeek NB, Dirven L, Schaardenburg D, Hulsmans HMJ, Kerstens PJSM, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70(8):1389–94.
   PubMed Web of Science ®Google Scholar
• Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin MM, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. N Engl J Med 2014;371(19):1781–92.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, et al. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 2016;75(1):52–8.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, et al. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology 2015;54(4):683–91.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, et al. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Ann Rheum Dis 2015;74(6):1150–5.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Yoon KS, Arthur K, Sang CB, Michael EW, Kishimoto M, et al. Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis 2014;73(3):595–9.
   PubMed Web of Science ®Google Scholar
• Georg S, Paul E, Tanaka Y, Gerd B, David SP, Esperanza N, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis 2016;75(8):1428–37.
   PubMed Web of Science ®Google Scholar
• Christopher JE, Bruno F, Hendrik SK, Tom WJH, Klaus K. Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology 2017;56:1847–56.
   PubMed Web of Science ®Google Scholar
• Sophie H, Adeline R, Alain C, Thomas B, Bruno F, Nathalie F, et al. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis. Ann Rheum Dis 2018;77:515–22.
   PubMedGoogle Scholar
• Yamanaka H, Tanaka E, Nakajima A, Furuya F, Ikari K, Taniguchi A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today’s treatment options. Mod Rheumatol 2020;30(1):1–6.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Saito K, Kojima T, Amano K, Yoshio T, Fukuda W, et al. No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 2013;23(5):945–52.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Hoshi D, Shimizu Y, Kobayashi A, Sugimoto N, et al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol 2015;25(4):503–13.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Gurkirpal S, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum 2003;49(6):784–8.
   PubMed Web of Science ®Google Scholar
• Inoue M, Kanda H, Tateishi S, Fujio K. Factors associated with discontinuation of glucocorticoids after starting biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients. Mod Rheumatol 2020;30(1):58–63.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Tanaka E, Inoue E, Shidara S, Sugimoto N, Seto Y, et al. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort. Mod Rheumatol 2018;28(3):461–7.
   PubMed Web of Science ®Google Scholar
• Roberto C, Carlo AS, Monica T, Carlomaurizio M. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol 2013;31:S9–S13.
   Google Scholar
• Priyanka V, Harlan S, Amy CC, Ted RM, Kaleb M. Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials. Arthritis Care Res 2016;68:1478–88.
   Google Scholar
• Katie B, Sujith S, Sam N, Fabiola A, Massimo G, Andrew PC, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatol 2019;58:1755–66.
   PubMed Web of Science ®Google Scholar
• Josef SS, Robert BM, Johannes WJB, Gerd RB, Maxime D, Andreas K, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685–99.
   PubMed Web of Science ®Google Scholar